(Q38261099)

1 September 2017

1 reference

title

Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial (English)

1 reference

1 September 2017

1 reference

1 reference

3

Bernard Escudier

1 reference

1 September 2017

Amikumar Mehta

1

1 reference

PubMed ID

25325825

1 September 2017

Guru Sonpavde

series ordinal

2

1 reference

PubMed ID

25325825

1 September 2017

language of work or name

English

0 references

publication date

1 August 2014

1 reference

1 September 2017

1 reference

1 September 2017

10

1 reference

1 September 2017

11

1 reference

1 September 2017

1819-1826

1 reference

Optimal management of metastatic renal cell carcinoma: current status

1 September 2017

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Development of second-generation VEGFR tyrosine kinase inhibitors: current status.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.120

21 January 2018

Identifiers

DOI

10.2217/FON.14.120

1 reference

1 September 2017

1 reference

PubMed ID

25325825